Product Description: NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis[1][2].
Applications: COVID-19-immunoregulation
Formula: C24H21N3O3
References: [1]Leber A, et.al. Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1 [published online ahead of print, 2019 Oct 25]. Drug Chem Toxicol. 2019;1-6./[2]Leber A, et al. Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. J Immunol. 2019;203(12):3407-3415.
CAS Number: 2389235-01-0
Molecular Weight: 399.44
Compound Purity: 98.47
Research Area: Inflammation/Immunology
Solubility: DMSO : 135 mg/mL (ultrasonic;warming)
Target: NOD-like Receptor (NLR)
Deutsch
English
